Evolution of the Healthcare Expenditure in Italy and Effects of Fingolimod Increased Prescribing in Second Line Treatment of Relapsing-Remitting Multiple Sclerosis:

Global & Regional Health Technology Assessment

MatteoRuggeri¹ 

关键词: Costs;    Fingolimod;    Healthcare expenditure;    Relapsing-remitting multiple sclerosis;   

DOI  :  10.5301/GRHTA.5000232

学科分类：医学（综合）

来源: Sage Journals

【 摘 要 】

PurposeTo analyse the evolution of impact on the healthcare expenditure of first and second line treatments for relapsing-remitting multiple sclerosis (RRMS) in Italy.MethodsAn economic model was developed in MSTM Excel (2010) and populated with data from three of the main Regions (Lombardy, Lazio, and Sicily) considered representative in Italy for location (North, Centre and South, respectively), population, and care organisation. Input data were retrieved from published sources and validated by a Board* of experts. The analysis considers an average from regional healthcare resource consumption, and national tariffs were used to economically quantify it. A sensitivity analysis was performed varying the market shares of second line treatments (fingolimod and natalizumab).*I nomi dei membri del Board sono riportati a fine articoloResultsThe results show that the total drug expenditure is €542,279,468 for both first and second line treatments. Among second line treatments, fingolimod showed to be less expen...

【 授权许可】

CC BY